Aligos Therapeutics
ALGS
34 hedge funds and large institutions have $64.5M invested in Aligos Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 6 closing their positions.
340% more capital invested
Capital invested by funds: $14.7M → $64.5M (+$49.9M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
26% more funds holding
Funds holding: 27 → 34 (+7)
8.31% less ownership
Funds ownership: 55.11% → 46.8% (-8.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.05M |
| 2 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$1.33M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.24M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$637K |
| 5 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
+$591K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.73M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$796K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$522K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$263K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$227K |
ALGS Hedge Fund Activity: Q4 2024 in Review
34 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q4 2024, worth a combined $64.5M — up 340% from $14.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ALGS positions and 6 closed out — a net gain of 7 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $2.05M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.73M sold.
- 34 institutional investors held Aligos Therapeutics (ALGS) as of Q4 2024, up from 27 in Q3 2024.
- Funds reported $64.5M of Aligos Therapeutics stock for Q4 2024, up 340% quarter-over-quarter.
- 13 funds opened new Aligos Therapeutics positions in Q4 2024 and 6 closed out, a net change of +7 holders.
- The largest Aligos Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $2.05M added.
- The largest Aligos Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $2.73M sold.
Based on aggregated 13F filings for Q4 2024.